CompletedNCT00216476
About this title
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
Read the official source — NCT00216476Official study titleCONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness
This study has finished and is no longer accepting participants.
Multiple locations, including Hall in TirolSchizophreniaMedication studyAges 18+
- Countries
- France, United Kingdom, Austria, + 21 others
- Sponsor
- Janssen-Cilag International NV
CompletedNCT03207048
Official study titleRepetitive Transcranial Magnetic Stimulation (rTMS) to Improve Cognitive Function and Prevent Relapses in Bipolar Patients
This study has finished and is no longer accepting participants.
In GuangzhouBipolarityDevice studyAges 18–60
- Countries
- China
- Sponsor
- Guangzhou Psychiatric Hospital
CompletedNCT00249171
About this title
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
Read the official source — NCT00249171Official study titleComparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 16+
- Countries
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
TerminatedNCT00256997
Official study titlePragmatic Randomized Trial of Risperdal Consta Versus Oral Atypical Antipsychotics in Poorly Adherent Subjects With Schizophrenia in a Routine Care Setting
This study ended early.
Multiple locations, including DandenongSchizophreniaMedication studyAges 18–65
- Countries
- Australia, Canada, United Kingdom, + 1 other
- Sponsor
- Janssen-Ortho Inc., Canada
CompletedNCT00167479
About this title
A Study of Risperidone Monotherapy in Bipolar Anxiety
Read the official source — NCT00167479Official study titleA Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including TampaBipolarity, AnxietyMedication studyAges 18+
- Countries
- United States
- Sponsor
- University of South Florida
CompletedACTRN12621001365853
Official study titleA Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RLS103 (CBD-Technosphere® Inhalation Powder) in Healthy Adult Volunteers
This study has finished and is no longer accepting participants.
In HerstonAnxietyInterventional studyAges 18–55
- Countries
- Australia
- Sponsor
- Receptor Life Sciences Australia Pty Ltd
CompletedNCT01234779
Official study titleA Phase II, Multi-center, Randomized, 4-week, Double-blind, Parallel Group, Placebo and Active-controlled Trial of the Safety and Efficacy of RO4917838 vs. Placebo in Patients With an Acute Exacerbation of Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States, Romania, Russia, + 2 others
- Sponsor
- Hoffmann-La Roche
CompletedNCT01192906
Official study titleA Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
This study has finished and is no longer accepting participants.
Multiple locations, including CarsonSchizophreniaMedication studyAges 18+
- Countries
- United States, Canada, Brazil, + 11 others
- Sponsor
- Hoffmann-La Roche
CompletedNCT01235559
Official study titlePhase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.
This study has finished and is no longer accepting participants.
Multiple locations, including Costa MesaSchizophreniaMedication studyAges 18+
- Countries
- United States, Bulgaria, China, + 4 others
- Sponsor
- Hoffmann-La Roche
CompletedNCT01235585
Official study titlePhase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.
This study has finished and is no longer accepting participants.
Multiple locations, including CarsonSchizophreniaMedication studyAges 18+
- Countries
- United States, Canada, Brazil, + 11 others
- Sponsor
- Hoffmann-La Roche
CompletedNCT00616798
Official study titleRandomized, Double-blind, Placebo-controlled add-on Trial of the Safety and Efficacy of RO4917838 in Outpatients on Select Atypical Antipsychotics With Prominent Negative or Disorganized Thought Symptoms
This study has finished and is no longer accepting participants.
Multiple locations, including Granada HillsSchizophreniaMedication studyAges 18–60
- Countries
- United States, France, Austria, + 7 others
- Sponsor
- Hoffmann-La Roche
CompletedNCT01192867
Official study titleA Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18+
- Countries
- United States, Australia, France, + 11 others
- Sponsor
- Hoffmann-La Roche
